Celldex Therapeutics, Inc. Net Income
Celldex Therapeutics, Inc. (CLDX) reported Net Income of -$73.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Celldex Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$73.50M.
- Celldex Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$78.69M.
- Celldex Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$81.32M.
- Celldex Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$67.04M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$73.50M 10-Q · filed 2026-08-06 | -$152.19M 10-Q · filed 2026-08-06 | -$233.50M derived: sum of 3 quarters · filed 2026-08-06 | -$300.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$78.69M 10-Q · filed 2026-08-06 | -$160.00M derived: sum of 2 quarters · filed 2026-08-06 | -$227.05M derived: sum of 3 quarters · filed 2026-08-06 | -$283.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$81.32M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | -$148.36M derived: sum of 2 quarters · filed 2026-04-29 | -$204.96M derived: sum of 3 quarters · filed 2026-08-06 | -$258.76M DEF 14A · filed 2026-04-29 |
| 2025-09-30 | -$67.04M 10-Q · filed 2025-11-10 | -$123.64M derived: sum of 2 quarters · filed 2026-08-06 | -$177.44M 10-Q · filed 2025-11-10 | -$224.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$56.60M 10-Q · filed 2026-08-06 | -$110.40M 10-Q · filed 2026-08-06 | -$157.49M derived: sum of 3 quarters · filed 2026-08-06 | -$199.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$53.80M 10-Q · filed 2026-08-06 | -$100.89M derived: sum of 2 quarters · filed 2026-08-06 | -$143.01M derived: sum of 3 quarters · filed 2026-08-06 | -$178.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$47.09M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | -$89.21M derived: sum of 2 quarters · filed 2026-04-29 | -$125.06M derived: sum of 3 quarters · filed 2026-04-29 | -$157.86M DEF 14A · filed 2026-04-29 |
| 2024-09-30 | -$42.12M 10-Q · filed 2025-11-10 | -$77.96M derived: sum of 2 quarters · filed 2025-11-10 | -$110.77M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$35.84M 10-Q · filed 2025-11-10 | -$68.65M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$32.81M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | -$141.43M DEF 14A · filed 2026-04-29 | |||
| 2022-12-31 | -$112.33M DEF 14A · filed 2026-04-29 | |||
| 2021-12-31 | -$70.51M DEF 14A · filed 2026-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |